Clinical Trial Update: Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating perioperative zanidatamab with chemotherapy for HER2-positive gastroesophageal cancer; the trial is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroesophageal Cancer

Drugs mentioned

• Zanidatamab

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Gastroesophageal Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING